Boothbay Fund Management’s Arcus Biosciences RCUS Stock Holding History

Boothbay Fund Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-175,700	Closed	-$3.15M	–	1922
2023 Q3	$3.15M	Sell	175,700 -100,000	-36%	-$2.01M	0.07%	356
2023 Q2	$5.6M	Buy	275,700 +104,400	+61%	+$1.99M	0.12%	186
2023 Q1	$3.12M	Buy	171,300 +114,900	+204%	+$2.2M	0.06%	466
2022 Q4	$1.17M	Buy	+56,400	New	+$1.55M	0.03%	830
2022 Q2	–	Sell	-123,200	Closed	-$3.89M	–	2599
2022 Q1	$3.89M	Buy	123,200 +92,600	+303%	+$3.1M	0.09%	292
2021 Q4	$1.24M	Buy	+30,600	New	+$1.19M	0.03%	663
2021 Q3	–	Sell	-28,700	Closed	-$788K	–	2135
2021 Q2	$788K	Buy	28,700 +28,413	+9,900%	+$812K	0.03%	801
2021 Q1	$806K	Buy	+287	New	+$9.99K	0.03%	708

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boothbay Fund Management's RCUS Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 154,264 shares worth $4.76M. The stake represents 0.06% of the portfolio and ranks #374 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in RCUS as recently as Q2 2025.

Boothbay Fund Management first reported a position in RCUS in Q1 2022 and has held it in 11 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Boothbay Fund Management held 154,264 shares of Arcus Biosciences worth $4.76M as of Q2 2026.
Arcus Biosciences was a new Boothbay Fund Management position in Q2 2026.
Arcus Biosciences made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #374 holding.
Boothbay Fund Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 11 quarters since.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.